 "Merck rallies 9% on good March quarter results; stock hits new high")
Procter & Gamble Health Limited (formerly Merck Limited) shares hit a new high of Rs 4,042, up 9 per cent, on the BSE in an otherwise subdued market after the company reported strong March quarter earnings (Q1CY19). In comparison, the S&P BSE Sensex was marginally down by 0.04 per cent at 37,449 points at 02:01 pm.
The stock surpassed its previous high of Rs 3,990, recorded on April 9 in intra-day trade.
The pharmaceutical company’s profit after tax rose 79 per cent at Rs 40.7 crore in Q1CY19 driven by high interest income and operational efficiencies. It had a profit of Rs 22.7 crore in year-ago quarter.
Total revenue grew 22.2 per cent at Rs 249 crore against Rs 204 crore in previous year quarter. The strong revenue growth driven by a strong performance across brands, growth in exports, higher interest income and improved execution.
Procter & Gamble Health is one of India's largest vitamins, minerals and supplements (VMS) companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life.
The management said with a brand portfolio backed by science and trusted by doctors, pharmacists and consumers, and the best of consumer health capabilities and cultures, the company was working towards creating a much stronger presence in India's fast-growing consumer health industry.
Meanwhile, the board of directors of the company, in its meeting held on February 27, had declared a dividend of Rs 440 per equity share, for the financial year ended December 31, 2018, which includes a one-time special dividend of Rs 416 per share on account of gain on business transfer.
Last year, Merck had transferred biopharma, performance materials and life science businesses to group entity Merck Life Science for an overall consideration of Rs 1,052 crore.
The stock will turn ex-date for dividend on May 23, 2019.
The stock surpassed its previous high of Rs 3,990, recorded on April 9 in intra-day trade.
The pharmaceutical company’s profit after tax rose 79 per cent at Rs 40.7 crore in Q1CY19 driven by high interest income and operational efficiencies. It had a profit of Rs 22.7 crore in year-ago quarter.
Total revenue grew 22.2 per cent at Rs 249 crore against Rs 204 crore in previous year quarter. The strong revenue growth driven by a strong performance across brands, growth in exports, higher interest income and improved execution.
Procter & Gamble Health is one of India's largest vitamins, minerals and supplements (VMS) companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life.
The management said with a brand portfolio backed by science and trusted by doctors, pharmacists and consumers, and the best of consumer health capabilities and cultures, the company was working towards creating a much stronger presence in India's fast-growing consumer health industry.
Meanwhile, the board of directors of the company, in its meeting held on February 27, had declared a dividend of Rs 440 per equity share, for the financial year ended December 31, 2018, which includes a one-time special dividend of Rs 416 per share on account of gain on business transfer.
Last year, Merck had transferred biopharma, performance materials and life science businesses to group entity Merck Life Science for an overall consideration of Rs 1,052 crore.
The stock will turn ex-date for dividend on May 23, 2019.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%